ライフサイエンスコーパス: percentage point

1 ninferiority for this end point (margin, -10 percentage points).

2 rity analysis (margin of noninferiority, 7.5 percentage points).

3 erence of 39 percentage points (CI, 23 to 53 percentage points).

4 ill substantial even with a KDPI of 100 (>16 percentage points).

5 of the fitted models (expressed in absolute percentage points).

6 limited effect on variability (COVs within 3 percentage points).

7 riority for the primary end point (margin, 6 percentage points).

8 the prespecified noninferiority margin of 1 percentage point.

9 a substantial increase of precision by 19.2 percentage points.

10 prespecified noninferiority margin was 1.75 percentage points.

11 ch were below the noninferiority margin of 4 percentage points.

12 lowest and highest educational groups was 20 percentage points.

13 end point, the noninferiority margin was 7.5 percentage points.

14 re biopsy) were simultaneously reduced by 20 percentage points.

15 outcome, with a noninferiority margin of 10 percentage points.

16 ephritis, with a noninferiority margin of 15 percentage points.

17 oninferiority was tested with a margin of 10 percentage points.

18 confidence interval -13.8 to 2.8; P = .193) percentage points.

19 Each day of delay decreased preference by 13 percentage points.

20 the prespecified noninferiority margin of -9 percentage points.

21 e-black gap in influenza vaccination was 9.9 percentage points.

22 ntrast, reduced the penalty difference, +6.6 percentage-points.

23 e severe), absolute differences +13.9, +20.5 percentage-points.

24 ce, 0.5 percentage point [95% CI, 0.4 to 0.6 percentage point]).

25 estimated to have absolute reductions of 4.6 percentage points (0.3-8.9) in total mortality and of 4.

26 ductions in prevalence (monthly trend -0.023 percentage points; -0.044 to -0.003), which were driven

27 ints (0.3-8.9) in total mortality and of 4.6 percentage points (1.2-8.0) in post-transition mortality

28 CI -0.73 to 2.28) in Lagos, Nigeria, to 3.64 percentage points (2.81 to 4.47) in Ghana, according to

29 orting a controlling partner (marginal RD in percentage points = 3.0, 95% CI 1.3, 4.6; p < 0.001), ex

30 -0.82 to -0.50) with poorer sanitation (-28 percentage points, -32 to -24).

31 e (oral group vs. intravenous group) of -1.4 percentage points (90% confidence interval [CI], -4.9 to

32 hweight of -31 g (95% CI -85 to 22) and 1.56 percentage point (95% CI -1.26 to 4.38) increased risk o

33 95, 95% CI 0.75-1.21; p=0.70), with only a 1 percentage point (95% CI -2 to 3) change in 5-year event

34 weight of -60 g (95% CI -86 to -34) and 2.15 percentage point (95% CI 1.07 to 3.24) increased risk of

35 ion of the bundle was associated with a 10.8 percentage point (95% CI = -17.9 to -3.7, p = 0.003) red

36 The between-group difference was -0.3 percentage point (95% CI, -1.2 to 0.4 percentage point;

37 ntervention period, for a difference of +5.1 percentage point (95% CI, 3.0 percentage points to 7.2 p

38 he EFV group, corresponding with a RD of 0.3 percentage point (95% CI: -2.7, 3.3), and HR was 1.08 (9

39 e EFV group, corresponding with a RD was 0.3 percentage point (95% CI: -3.0, 3.7), and HR was 1.09 (9

40 age (15-49 years) varied from as low as 0.77 percentage points (95% CI -0.73 to 2.28) in Lagos, Niger

41 all women across all nine settings was 1.92 percentage points (95% CI 1.14 to 2.70).

42 alence of obesity from 1966 to 2019 was 19.8 percentage points (95% CI 16.2 to 23.5, p < 0.0001) and

43 s (95% CI 16.2 to 23.5, p < 0.0001) and 20.0 percentage points (95% CI 16.4 to 23.7, p < 0.0001) grea

44 ty for men and women, respectively, were 8.5 percentage points (95% CI 6.3 to 10.7, p < 0.0001) and 1

45 ts (95% CI 6.3 to 10.7, p < 0.0001) and 12.6 percentage points (95% CI 9.6 to 15.6, p < 0.0001) great

46 erence in the change from baseline was -0.18 percentage points (95% CI, -0.38 to 0.02, P = 0.08).

47 was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001).

48 agement group), the risk difference of -11.0 percentage points (95% CI, -18.4 to -3.5) was outside th

49 (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose,

50 n the EFV400 group, with a difference of 4.7 percentage points (95% CI, -4.6 to 14.0).

51 val [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose

52 5% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg do

53 oup, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001).

54 ith a mean between-group difference of -4.51 percentage points (95% CI, -5.93 to -3.10) (P<0.001).

55 oup, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001).

56 lacebo group, for a risk difference of -0.46 percentage points (95% CI, -7.8 to 6.8).

57 Risk for BSI was 23 percentage points (95% CI, 10 to 35 percentage points) l

58 The difference of 7.9 percentage points (95% CI, 4.1 to 11.8) showed noninferi

59 041), and past-30-day binge drinking, by 3.5 percentage points (95% CI: -0.1, 7.2, p = 0.058), among

60 pre-diagnosis, a significant reduction by 13 percentage points (95% CI: -16.9, - 9.4; p-value: < 0.00

61 increases in past-30-day alcohol use, by 5.9 percentage points (95% CI: 0.3, 12.2; p = 0.041), and pa

62 as a result of the shutdown, by 4 additional percentage points (95% CI: 3 to 5 percentage points [p.p

63 ower levy sugar threshold had fallen by 33.8 percentage points (95% CI: 33.3-34.4, p < 0.001).

64 uced probability of being underweight of 1.4 percentage points (95% confidence interval -0.02, -0.01)

65 reduced probability of being stunted of 1.9 percentage points (95% confidence interval -0.02, -0.01)

66 n the EFV400 group, with a difference of 5.5 percentage points (95% confidence interval [CI], -1.6 to

67 tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to

68 group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 t

69 icted a placebo corrected net effect of 34.3 percentage points (95% confidence interval [CI], 13.3-54

70 7 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2;

71 he open group (between-group difference, 0.5 percentage point [95% CI, -11.3 to 12.3 percentage point

72 re for AMI (17.2% vs. 16.9%; difference, 0.3 percentage point [95% CI, 0.1 to 0.5 percentage point]),

73 pneumonia (16.5% vs. 16.0%; difference, 0.5 percentage point [95% CI, 0.4 to 0.6 percentage point]).

74 ed with lower Healthy Purchasing Score (-4.8 percentage points [95% CI -8.6 to -1.0]; P = 0.02), high

75 [26.6] in the control group (difference 32.0 percentage points [95% CI 18.5-45.5; p<0.0001]).

76 .00 to 1.10]; absolute risk difference, 0.93 percentage points [95% CI, -0.01 to 1.88] percentage poi

77 , P = .02), and very low birth weight (-0.13 percentage points [95% CI, -0.25 to -0.01], P = .04).

78 -0.02], P = .05), very preterm birth (-0.14 percentage points [95% CI, -0.26 to -0.02], P = .03), lo

79 ive DDD coefficient for preterm birth (-0.43 percentage points [95% CI, -0.84 to -0.02], P = .05), ve

80 57 to 0.92]; absolute risk difference, -0.51 percentage points [95% CI, -0.90 to -0.12 percentage poi

81 to -0.02], P = .03), low birth weight (-0.53 percentage points [95% CI, -0.96 to -0.10], P = .02), an

82 practice (56.7% vs 70.6%; difference, -13.9 percentage points [95% CI, -14.4 to -13.3]; P < .001).

83 6.0% in the rituximab group (difference, 9.2 percentage points [95% CI, -5.5 to 23.3 percentage point

84 s and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazar

85 neficiaries (9.4% vs 17.8%; difference, -8.3 percentage points [95% CI, -8.7 to -8.0]; P < .001) or t

86 IABP [16.0%]; absolute risk difference, 15.4 percentage points [95% CI, 12.5-18.2]; P < .001).

87 rural areas (12.7% vs 6.4%; difference, 6.3 percentage points [95% CI, 6.0 to 6.7]; P < .001) but le

88 0.3%) in the placebo group (difference, -6.4 percentage points [95% confidence interval, -11.4 to -1.

89 IABP (34.1% [absolute risk difference, 10.9 percentage points {95% CI, 7.6-14.2}; P < .001) and also

90 tic body radiotherapy group (difference -1.9 percentage points, 95% CI -6.2 to 2.4; p=0.38).

91 8) (adjusted difference-in-differences: 12.0 percentage points, 95% CI 1.0-23.0; P = 0.03).

92 6.7% in the surgery group (difference, -1.4 percentage points; 95% Bayesian credible interval for di

93 crease was associated with immediate (-0.745 percentage points; 95% CI -1.378 to -0.112) and sustaine

94 n 27 (17.3%), respectively (difference, -3.9 percentage points; 95% CI for noninferiority, -11.9 to 4

95 g aspirin plus clopidogrel (difference, -8.2 percentage points; 95% CI for noninferiority, -14.9 to -

96 gulation plus clopidogrel (difference, -14.3 percentage points; 95% CI for noninferiority, -25.0 to -

97 ients (9.9%), respectively (difference, -0.2 percentage points; 95% CI for noninferiority, -4.7 to 4.

98 .34; P = 0.72) or in 30-day mortality (-0.03 percentage points; 95% CI, -0.20 to 0.14; P = 0.72).

99 al change in 30-day readmission rates (-0.10 percentage points; 95% CI, -0.53 to 0.34; P = 0.72) or i

100 7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4).

101 pse by day 14 (between-group difference, 1.7 percentage points; 95% CI, -0.7 to 4.1).

102 n the early-endoscopy group (difference, 3.1 percentage points; 95% CI, -1.9 to 8.1).

103 8% in the adalimumab group (difference, -9.3 percentage points; 95% CI, -18.9 to 0.4).

104 of chest imaging in 51.9% (difference, -17.6 percentage points; 95% CI, -19.2 to -15.9).

105 two groups (2.9% and 3.7%; difference, -0.8 percentage points; 95% CI, -2.4 to 0.9).

106 .6% and 85.1%, respectively (difference, 2.5 percentage points; 95% CI, -2.4 to 7.4).

107 percentages were 15% and 6% (difference, -9 percentage points; 95% CI, -29 to 11).

108 eived oral therapy (adjusted difference, 0.4 percentage points; 95% CI, -3.7 to 4.5), a result that m

109 after CABG (3.3% vs. 5.2%; difference, -1.9 percentage points; 95% CI, -3.8 to 0), although the inci

110 in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5).

111 4% and 18.2%, respectively (difference, -1.8 percentage points; 95% CI, -4.7 to 1.0).

112 .8%) in the sedation group (difference, -2.5 percentage points; 95% CI, -4.8 to -0.7 [unadjusted for

113 placebo (least-squares mean difference, -26 percentage points; 95% CI, -44 to -9; P = 0.004).

114 the placebo group (weighted difference, 2.0 percentage points; 95% CI, -5.2 to 7.8).

115 158], respectively; difference in risk, -0.2 percentage points; 95% CI, -5.5 to 5.0; P = 0.002 for no

116 3% and 83.2%, respectively; difference, -1.9 percentage points; 95% CI, -8.0 to 4.3).

117 -repair group (between-group difference, 1.3 percentage points; 95% CI, 0.1 to 2.6).

118 BG group (in 13.0% vs. 9.9%; difference, 3.1 percentage points; 95% CI, 0.2 to 6.1).

119 eral-oxygen group had died (difference, 14.0 percentage points; 95% CI, 0.7 to 27.2).

120 an infant) (23.6% vs. 17.0%; difference, 6.7 percentage points; 95% CI, 0.8 to 11.9).

121 b and 13.3% with abatacept (difference, 16.8 percentage points; 95% CI, 10.4 to 23.2; P<0.001 for sup

122 20.0% in the control group (difference, 15.1 percentage points; 95% CI, 2.6 to 27.6).

123 97 patients), respectively (difference, 11.6 percentage points; 95% CI, 2.7 to 20.3).

124 f those in the placebo group (difference, 36 percentage points; 95% CI, 22 to 55).

125 te or partial remission (risk difference, 40 percentage points; 95% CI, 25 to 55; P<0.001 for both no

126 after CABG (16.9% vs. 10.0%; difference, 6.9 percentage points; 95% CI, 3.7 to 10.0).

127 atients who received placebo (difference, 58 percentage points; 95% CI, 36 to 74; P<0.001).

128 provement (39.7% vs. 27.7%; difference, 11.9 percentage points; 95% CI, 5.3 to 18.5; P<0.001).

129 the placebo group (absolute difference, 12.4 percentage points; 95% CI, 6.9 to 17.9; P<0.001).

130 .6% lower probability (absolute change: -8.3 percentage points; 95% CI: -14.9 to -1.7; P = 0.01) of c

131 4), or late-onset sepsis probability (-1.175 percentage points; 95% CI: -6.556, 4.205).

132 patients in the CABG group (difference, 2.8 percentage points; 95% confidence interval [CI], -0.9 to

133 in the 5-day group (adjusted difference, 0.7 percentage points; 95% confidence interval [CI], -0.9 to

134 ts) in the meropenem group (difference, -3.4 percentage points; 95% confidence interval [CI], -10.0 t

135 p (8.5% vs. 15.1%; absolute difference, -6.6 percentage points; 95% confidence interval [CI], -10.8 t

136 bo group (least-squares mean difference, -98 percentage points; 95% confidence interval [CI], -121 to

137 in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 t

138 d-treatment group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.0 to

139 37.0% in the sedated group (difference, 5.4 percentage points; 95% confidence interval [CI], -2.2 to

140 n the early-endoscopy group (difference, 2.3 percentage points; 95% confidence interval [CI], -2.3 to

141 ived oral therapy (adjusted difference, -0.4 percentage points; 95% confidence interval [CI], -2.8 to

142 beral-oxygen group had died (difference, 7.8 percentage points; 95% confidence interval [CI], -4.8 to

143 among nonusers of aspirin (difference, -4.3 percentage points; 95% confidence interval [CI], -5.0 to

144 1% and 82.7%, respectively; difference, -1.6 percentage points; 95% confidence interval [CI], -7.1 to

145 nservative management (risk difference, -4.1 percentage points; 95% confidence interval [CI], -8.6 to

146 tegravir ART at conception (difference, 0.20 percentage points; 95% confidence interval [CI], 0.01 to

147 ) in the normothermia group (difference, 4.5 percentage points; 95% confidence interval [CI], 0.1 to

148 conservative-strategy group (difference, 1.9 percentage points; 95% confidence interval [CI], 0.8 to

149 929 children) (between-group difference, 2.3 percentage points; 95% confidence interval [CI], 0.9 to

150 59.5% [88 of 148]; difference in risk, 22.8 percentage points; 95% confidence interval [CI], 12.8 to

151 umab group (31.3% vs. 22.5%; difference, 8.8 percentage points; 95% confidence interval [CI], 2.5 to

152 the placebo group (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to

153 2%) in the CPAP group (risk difference, 10.3 percentage points; 95% confidence interval [CI], 5.2 to

154 control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14

155 oxygen therapy or had died (difference, -3.0 percentage points; 95% confidence interval, -15.1 to 9.1

156 treated group (between-group difference, 3.1 percentage points; 95% confidence interval, -3.4 to 9.6;

157 .2%) in the placebo group (difference, -32.8 percentage points; 95% confidence interval, -46.8 to -18

158 n-group difference was not significant (0.82 percentage points; 95% confidence interval, -5.97 to 7.6

159 RD, -5.9 percentage points [CI, -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 1

160 tage point gap among women in Brazil and 3.3 percentage points among men in Argentina.

161 ine was negligible by difference in absolute percentage points among whites (2.6%) and blacks (4.8%)

162 onal unemployment rate has increased by 8.40 percentage points, an increase expected to result in mor

163 les increased newcomer rule compliance by >8 percentage points and increased the participation rate o

164 all survival at 10 years of approximately3% (percentage points) and 4%, respectively.

165 placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated differ

166 ity testing (with a prespecified margin of 6 percentage points) and superiority testing were performe

167 r noninferiority (noninferiority margin, 7.5 percentage points) and superiority.

168 r noninferiority (noninferiority margin, 7.5 percentage points) and superiority.

169 1.44 [1.42-1.47]; absolute difference: +7.4 percentage-points) and low socioeconomic status-serving

170 to -2.91), less bargaining power (-7 to -15 percentage points), and lived in poorer households (-0.6

171 ment into community-based ART delivery by 25 percentage points, and switching to second-line ART by 1

172 herapy group (899 participants) averaged 1.5 percentage points, and this difference declined to 0.2 t

173 RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD

174 erence, 0.3 percentage point [CI, 0.2 to 0.5 percentage point]), and pneumonia (16.5% vs. 16.0%; diff

175 vents and HbA(1c) <= 6.5% or reduced by >= 1 percentage point at 1 year posttransplant.

176 sulted in a between-group difference of 49.0 percentage points at 24 weeks.

177 centage was 17 percentage points (IQR, 12-22 percentage points) at week 96 among ART-naive children,

178 mall numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of

179 , and this difference declined to 0.2 to 0.3 percentage points by 3 years after the trial ended.

180 (P<0.001); the difference increased to -1.30 percentage points by 52 weeks.

181 ce, 0.3 percentage point [95% CI, 0.1 to 0.5 percentage point]), CHF (21.7% vs. 21.4%; difference, 0.

182 to 35%, for a between-group difference of 39 percentage points (CI, 23 to 53 percentage points).

183 ns were not significant (adjusted DID, -0.47 percentage point [CI, -1.0 to 0.06 percentage point]; P

184 int]), CHF (21.7% vs. 21.4%; difference, 0.3 percentage point [CI, 0.2 to 0.5 percentage point]), and

185 ) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points])

186 he open group (between-group difference, 6.0 percentage points [CI, -6.7 to 18.7 percentage points];

187 philic statin cDDDs (8.4% vs. 2.5%; RD, -5.9 percentage points [CI, -7.6 to -4.2 percentage points];

188 ng both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points])

189 astern part (11.9% vs 1.2%, difference: 10.7 percentage points, CI: 9.5-12.2).

190 oints, and switching to second-line ART by 1 percentage point compared with standard of care, as repo

191 ercentage point increase in OS (CI, 16 to 47 percentage points) compared with the antibiotic group.

192 c deficiency by a median of 11 (range: 4-18) percentage points, compared with the unadjusted prevalen

193 after enrollment misleadingly suggested a 38-percentage-point decline in admissions related to the in

194 ucoma-related distress score predicted a 2.4-percentage-point decrease in medication adherence.

195 A 15-percentage-point decrease in the saving rate of China ca

196 ariation of the W:T variance showed up to 40 percentage points deviation in the proportion with intak

197 We find a nearly 10 percentage point difference between Democrats and Republ

198 Detecting a 1.1-percentage point difference from the mean adjusted readm

199 were 13.52% for CAHs vs 11.44% for non-CAHs (percentage point difference, 2.08 [95% CI, 1.74 to 2.42]

200 7 [83%] of 360) for early clinical response (percentage-point difference 5.0, 95% CI -0.2 to 10.3) in

201 etween centers, with up to ten-fold and 57.4 percentage point differences.

202 12.4% and 13.4%, respectively, each only 0.5 percentage point different from the mean.

203 vada and Michigan) each experiencing over 16 percentage points employment displacement but accounting

204 monitoring increased viral suppression by 9 percentage points, enrolment into community-based ART de

205 control group (mean adjusted difference, 11 percentage points [equivalent to 2.6 hours per day]; 95%

206 feriority, with a noninferiority margin of 2 percentage points for the absolute difference) and PLATO

207 ce, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]).

208 rences were observed for melanoma, with a 17-percentage-point gain in sensitivity compared with the s

209 adiotherapy would yield the largest absolute percentage point gains in low-income countries (5.2, 0.3

210 4 percentage point gap), compared with a 3.7 percentage point gap among women in Brazil and 3.3 perce

211 h was observed in Honduras among women (21.6 percentage point gap), and in Peru among men (22.4 perce

212 tage point gap), and in Peru among men (22.4 percentage point gap), compared with a 3.7 percentage po

213 1984-2018 and observed a mean decline of 2.5 percentage points globally in the past three decades.

214 igh-accuracy test has specificity at least 3 percentage points greater than the moderate-accuracy tes

215 ek 12 (MOD, -4.6 percentage points; LOW -3.2 percentage points), greater phosphorylation of S6-kinase

216 0.5 percentage point [95% CI, -11.3 to 12.3 percentage points]; hazard ratio, 0.93 [CI, 0.67 to 1.30

217 nce, 6.0 percentage points [CI, -6.7 to 18.7 percentage points]; hazard ratio, 1.09 [CI, 0.80 to 1.49

218 sulting in 2.3 (95% CI: 1.9, 2.6) fatty acid percentage points higher erythrocyte n-3 LCPUFA than in

219 0% CI [-6.3, 27.2], P = 0.31), and were 42.8 percentage points higher in the prespecified exploratory

220 , 0-46 mL); and weekly mean hematocrit was 3 percentage points higher with liberal thresholds.

221 lted in 2.25 (95% CI: 1.88, 2.62) fatty acid percentage-point higher erythrocyte EPA + DHA in the fis

222 nomic status-serving (1.38[1.35-1.40]; +7.3% percentage-points) hospitals.

223 y 8-9 percentage points in Harlem and by 5-9 percentage points in Bangkok across regimens.

224 es in 5-year overall survival up to about 10 percentage points in either direction cannot be excluded

225 rest participants was 11.1 (95% CI 4.6-17.5) percentage points in female participants and 15.1 (9.6-2

226 covered acts decreases effectiveness by 8-9 percentage points in Harlem and by 5-9 percentage points

227 se symptoms) and a reduction of at least 0.5 percentage points in HbA1c, 5 mm Hg in SBP, or 10 mg/dL

228 pril, which had doubled in size to nearly 20 percentage points in June.

229 centage points in the icodec group and -1.15 percentage points in the glargine group, to estimated me

230 e in the glycated hemoglobin level was -1.33 percentage points in the icodec group and -1.15 percenta

231 We found an increase of eleven percentage points in the probability of signing the peti

232 The rate of change was also high (>1.4 percentage points) in Burkina Faso, Kinshasa (DR Congo),

233 int increase for upper-middle income and 0.4 percentage point increase for high income).

234 proved availability of targeted therapy (0.7 percentage point increase for upper-middle income and 0.

235 Of the 3.2-percentage point increase in administration's share of U

236 talization (CI, 9 to 20 fewer days) and a 32-percentage point increase in OS (CI, 16 to 47 percentage

237 itted to egg count data, we found that every percentage point increase in piped water coverage was as

238 r survival gains globally (data are absolute percentage point increase in survival 0.6, 95% UI 0.1-2.

239 argest survival gains in low-income (2.5-3.4 percentage point increase in survival) and lower-middle-

240 ) and lower-middle-income countries (2.4-6.1 percentage point increase), whereas upper-middle-income

241 als aged 30-59 years (0.43 [0.16-0.69] per 1 percentage-point increase in the unemployment rate.

242 ncrease in the CD4+ T-cell percentage was 17 percentage points (IQR, 12-22 percentage points) at week

243 IIX fibres from Week 0 to Week 12 (MOD, -4.6 percentage points; LOW -3.2 percentage points), greater

244 o 0.011), meaning that the risk was around 3 percentage points lower in the no co-trimoxazole group o

245 I was 23 percentage points (95% CI, 10 to 35 percentage points) lower in the FMT group; the FMT group

246 sed supplements increased the O3I by about 1 percentage point more than EE products.

247 g their late high school years were also 1.8 percentage points more likely to report current smoking

248 to same-sex marriage and abortion was 3 to 4 percentage points more prevalent than it would have been

249 f NH residents (N=2,233,392) of at least one percentage point (N=40 states).

250 ll, the annual growth rates exceeded the 1.4 percentage points needed to achieve the FP2020 goal of 1

251 venient only (95% CI 6-18; P < 0.001), and 2 percentage points (not significant) relative to free onl

252 for each participant by an increase of 13.88 percentage points of body-weight in the loading of the s

253 he tropics, with declines in CI of ~20 to 40 percentage points on average across the species in the A

254 ea under the receiver-operating curve of 5.4 percentage points (P <= 1.0 x 10(-9)).

255 er kilogram and the placebo group were -50.5 percentage points (P<0.001) and -24.2 percentage points,

256 the placebo group, for a difference of -38.3 percentage points (P<0.001).

257 r an estimated treatment difference of -1.06 percentage points (P<0.001); the difference increased to

258 additional percentage points (95% CI: 3 to 5 percentage points [p.p.]) in Denmark.

259 s -0.3 percentage point (95% CI, -1.2 to 0.4 percentage point; P = 0.38) (odds ratio, 0.82 [CI, 0.54

260 point (95% CI, 3.0 percentage points to 7.2 percentage points; P < .001).

261 93 percentage points [95% CI, -0.01 to 1.88] percentage points; P = .054).

262 centage point reduction (95% CI -2.3 to -0.6 percentage points; p = 0.001) in adolescent IDU, on aver

263 ID, -0.47 percentage point [CI, -1.0 to 0.06 percentage point]; P = 0.084).

264 51 percentage points [95% CI, -0.90 to -0.12 percentage points]; P = .009).

265 9.2 percentage points [95% CI, -5.5 to 23.3 percentage points]; P = 0.22).

266 2016 than in those adopting it in 2013: 23.4 percentage points (pp) (95% confidence interval, 13.9-32

267 reening coverage (cross-sectional study: +18 percentage points [pp], 95% CI 10-26, P < 0.001; longitu

268 wanda, from 44.4% to 78.9% of patients (34.5 percentage points [pp], 95% CI 27.2 to 41.7; p < 0.001),

269 rm, but had no impact on stunting (DD = -6.2 percentage points [pp], relative odds ratio [ROR]: 0.74,

270 PDMP mandates were associated with a 1.5 percentage point reduction (95% CI -2.3 to -0.6 percenta

271 otential spillover was associated with a 1.5-percentage point reduction among peers.

272 omes (>=50% reduction in SCL-20 score, >=0.5-percentage point reduction in HbA1c, >=5-mm Hg reduction

273 Direct effects were associated with a 3.2-percentage point reduction in victimization among seeds

274 control group (95% CI 13-26; P < 0.001), 12 percentage points relative to convenient only (95% CI 6-

275 nt distribution increased ORS coverage by 19 percentage points relative to the control group (95% CI

276 ction in use of modern contraception by 3.15 percentage points (relative decrease of 13.5%; 95% CI -4

277 p=0.0006) and increase in pregnancies by 3.2 percentage points (relative increase of 12%; 95% CI 1.6

278 e placebo group were -56.0, -52.9, and -38.5 percentage points, respectively (P<0.001 for all compari

279 .9 (95% CI 0.7-1.1) and 2.6 (95% CI 2.2-2.9) percentage points, respectively.

280 -50.5 percentage points (P<0.001) and -24.2 percentage points, respectively.

281 omes by an additional 0.4, 0.4, 0.2, and 0.2 percentage points, respectively.

282 and vaginal breech deliveries by 0.7 and 1.0 percentage points, respectively: around 4,196 and 6,061

283 Downscaling experiments show a 10-percentage-point shift from the slow-moving to the fast-

284 RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.

285 erence of +5.1 percentage point (95% CI, 3.0 percentage points to 7.2 percentage points; P < .001).

286 revalence rates from an estimated 0.7 to 1.4 percentage points to achieve the goal.

287 Decreases in LVEF from a baseline of >= 10 percentage points to an absolute value of < 50% followin

288 tration snapshot approach and a margin of 10 percentage points to define the non-inferiority of dorav

289 ive design, yielded a risk difference of -19 percentage points (upper boundary of the 97.5% confidenc

290 at between the 20-mg and 5-mg groups was 0.7 percentage points (upper boundary of the 98.75% CI, 2.8)

291 e between the 20-mg and 10-mg groups was 1.2 percentage points (upper boundary of the 98.75% confiden

292 of U.S. health expenditures since 1999, 2.4 percentage points was due to growth in private insurers'

293 group difference in the primary end point in percentage points was more than -10.

294 A difference of at least 10 percentage points was prespecified as a substantial diff

295 follow-up; a noninferiority margin of -12.5 percentage points was used in the primary analysis.

296 A noninferiority margin of 10 percentage points was used.

297 An increase in unemployment rate of 1 percentage-point was associated with a 0.50 increase per

298 Although non-inferiority (margin of 10 percentage points) was established for the first major s

299 cated hemoglobin level had decreased by 0.64 percentage points with liraglutide and increased by 0.42

300 oints with liraglutide and increased by 0.42 percentage points with placebo, for an estimated treatme